Acetyl-EEMQRR sequence mimics N-terminal domain of SNAP-25 synaptic protein, competing at SNARE complex assembly. Reduces acetylcholine vesicle release frequency at neuromuscular junctions in skin. Reduces repetitive facial muscle microtension that generates dynamic expression lines over time.
Studies have administered: Topical 5–10% concentrations in research formulations; clinical products typically 5%
Blanes-Mira (2002): original SNAP-25 competition mechanism demonstrated. Multiple in vivo trials: 10–17% wrinkle depth reduction at 30 days. Combined with SNAP-8: enhanced effect vs either alone. Widely replicated in cosmetic science literature.
Excellent topical tolerability across studies; minimal systemic exposure; no botulinum toxin cross-reactivity concerns
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Acetyl Hexapeptide-3 (Argireline) — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat